Results 101 to 110 of about 7,712,957 (388)

Interpreting and Reporting Results Based on Patient-Reported Outcomes [PDF]

, 2007
This article deals with the incorporation of patient-reported outcomes (PROs) into clinical trials and focuses on issues associated with the interpretation and reporting of PRO data.
Revicki, Dennis A., Erickson, Pennifer A., Sloan, Jeff A., Dueck, Amylou, Guess, Harry, Santanello, Nancy C.   +5 more
core   +1 more source

Subpar reporting of pre‐analytical variables in RNA‐focused blood plasma studies

Molecular Oncology, EarlyView.
Pre‐analytical variables strongly influence the analysis of extracellular RNA (cell‐free RNA; exRNA) derived from blood plasma. Their reporting is essential to allow interpretation and replication of results. By evaluating 200 exRNA studies, we pinpoint a lack of reporting pre‐analytical variables associated with blood collection, plasma preparation ...
Céleste Van Der Schueren, Philippe Decruyenaere, Francisco Avila Cobos, Johanna Bult, Jill Deleu, Laudonia Lidia Dipalo, Hetty Hilde Helsmoortel, Eva Hulstaert, Annelien Morlion, Elena Ramos Varas, Kathleen Schoofs, Wim Trypsteen, Eveline Vanden Eynde, Hanne Van Droogenbroeck, Kimberly Verniers, Jo Vandesompele, Anneleen Decock   +16 more
wiley   +1 more source

International phase 1 study protocol to develop a health state classification system for a preference-based measure for women with breast cancer: the BREAST-Q Utility module

BMJ Open, 2020
Introduction Concerns unique to women with breast cancer can include impact of cancer on body image, sexual well-being and changes in breast appearance and sensation.
Andrea L Pusic, Stefan J Cano, Anne Klassen, Feng Xie, Manraj Kaur, Louise Bordeleau   +5 more
doaj   +1 more source

Effectiveness of delayed-release dimethyl fumarate on patient-reported outcomes and clinical measures in patients with relapsing-remitting multiple sclerosis in a real-world clinical setting: PROTEC. [PDF]

, 2019
Ensaio clínico PROTEC, Protocolo nº 109MS408Abstract BACKGROUND: Patient-reported outcomes (PRO) and clinical outcomes give a broad assessment of relapsing-remitting multiple sclerosis (RRMS) disease.
Berger, T, Brambilla, L, Brochet, B, Giacomini, PS, Montalbán, X, Salgado, Salgado, AV, e outros   +5 more
core   +1 more source

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

Molecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink, Leon W. M. M. Terstappen, Eshwari Dathathri, Khrystany Isebia, Jaco Kraan, John Martens, Ruchi Bansal   +6 more
wiley   +1 more source

Systematic review of the use of translated patient-reported outcome measures in cancer trials

Trials, 2021
Background Patient-reported outcomes (PROs) are used in clinical trials to assess the effectiveness and tolerability of interventions. Inclusion of participants from different ethnic backgrounds is essential for generalisability of cancer trial results ...
A. L. Slade, A. Retzer, K. Ahmed, D. Kyte, T. Keeley, J. Armes, J. M. Brown, L. Calman, A. Gavin, A. W. Glaser, D. M. Greenfield, A. Lanceley, R. M. Taylor, G. Velikova, G. Turner, M. J. Calvert   +15 more
doaj   +1 more source

The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events

Journal of Patient-Reported Outcomes, 2018
BackgroundThe Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) was developed by the National Cancer Institute as an adverse event assessment system to evaluate patients’ symptoms, which tend to be ...
T. Kawaguchi, Kanako Azuma, M. Sano, Soan Kim, Yosuke Kawahara, Yoko Sano, Tomohide Shimodaira, K. Ishibashi, T. Miyaji, E. Basch, Takuhiro Yamaguchi   +10 more
semanticscholar   +1 more source

PEPFAR Public Health Evaluation - Care and Support - Phase 2 Uganda [PDF]

, 2009
Phase 2 consisted of a longitudinal cohort study to measure patient-reported outcomes of care and support, a costing survey, and qualitative interviews to understand patient and carer ...
Claire Nsubuga Kwebiiha, Eve Namisango, Faith Mwangi-Powell, Geoffrey Banga Nkurunziza, Irene J. Higginson, Jennifer Kataike, Julia Downing, Richard A. Powell, Richard Harding, Scott Moreland, Suzanne Penfold, Victoria Simms   +11 more
core  

Physical Function and Quality of Life After Resection of Mobile Spine Chondrosarcoma. [PDF]

, 2019
Study Design:Retrospective cohort study. Objectives:(1) To assess patient-reported outcomes-physical function, pain, and quality of life-in patients who underwent resection of a mobile spine chondrosarcoma.
Chen, Yen-Lin E, DeLaney, Thomas F, Hartveldt, Stefan, Hornicek, Francis J, Janssen, Stein J, Paulino Pereira, Nuno Rui, Schwab, Joseph H, Stoop, Nicky   +7 more
core   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source